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tions or, in particular, the development and/or deterioration of
autoimmunity, should be seriously weighted in the ﬁnal decision
of the clinician.
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E-mail address: dalekos@med.uth.grclinical practice [6], with prednisolone (initial dose 1 mg/kg/day)
plus mycophenolate mofetil (2 g/day), resulting in complete
remission of AIH within 2 months, as attested by normal trans-
aminases and IgG levels. Prednisolone was discontinued at the
4th month, but 2 months later a biochemical relapse was
observed (ALT and AST up to three times the upper normal limit
but normal IgG) and again prednisolone was started at a low dose
(20 mg/day). At the time of this writing (12 months from initial
treatment and 6 months from re-treatment), the patient has
complete response under mycophenolate monotherapy (3-month
prednisolone off treatment).
This report adds to a small but increasing number of pub-
lished cases of AIH induced by TNFa blockade, highlighting the
dual effects that anti-TNFa therapy might have, particularly in
the case of AIH [7,8]. The paradox of anti-TNFa therapy in AIH
is mainly attributed to the disruption of the regulatory role of
TNFa signaling on the immune system. TNFa blockade interferes
with the normal cytotoxic T lymphocyte suppression of self-reac-
tive B-cell population, leading to autoantibody production, a hall-
mark of AIH diagnosis, although from the pathophysiological
point of view the role of autoantibodies in AIH development is
obscure. Furthermore, anti-TNFa therapy disrupts the TNFa-
mediated apoptosis of activated T lymphocytes resulting in
unregulated lymphocyte activation [9].
Moreover, treatment with inﬂiximab predisposes patients to
severe infections, as clearly demonstrated by this series of Weil-
er-Normann et al. [1], where 7 out of 11 patients treated with inf-
liximab, had serious bacterial or viral infections. Indeed, the high
risk for serious infections is a well-recognized side effect of anti-
TNFa therapy in patients with rheumatoid arthritis or inﬂamma-
tory bowel disease [10]. However, the increased odds ratio might
be even more crucial in patients with advanced liver disease (in
this series [1], 7 out of 11 patients had histologically conﬁrmed
cirrhosis), since the already existing dysregulation of the immune
system due to cirrhosis, may further increase the risk of serious
infectious complications after anti-TNFa treatment.
Therefore, the induction of autoimmunity along with the pos-
sibility of lethal infections constitutes the ‘‘dark side’’ of anti-
TNFa therapy in AIH. In our opinion, TNFa blockade could be a
therapeutic option for refractory cases of AIH, taking into account
its reported efﬁcacy and the potential role of TNFa in the patho-
genesis of AIH [2,3]. However, we strongly believe that anti-TNFa
treatment for AIH could be a rational option only after alternative
regimens with a safer side-effect proﬁle, such as cyclosporine,
tacrolimus or mycophenolate mofetil [6] have failed. In any case,
the incapability to predict efﬁciently the ‘‘unforeseen complica-
tions’’ of such a treatment, such as the emergence of severe infec-
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e would like to thank Saitis and colleagues [1] for their view on
Fa antagonist use in difﬁcult-to-treat autoimmune hepatitis
IH) and for the addition of pathophysiological mechanisms,
ich may explain the effects of this treatment in AIH [2].
There are around 40 case reports in the literature – including
the most recent one presented here – that have described the
development of AIH or an immune mediated hepatitis after
administration of anti-TNFa agents such as inﬂiximab [3], ada-
limumab [4] and etanercept [5]. Whether the induction of AIH
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is limited to patients with a genetic susceptibility to AIH is
unknown but seems likely. In other patients, an immune medi-
ated hepatitis may develop under TNFa blockade, which does
not necessarily evolve into the typical chronic course of AIH.
The difference between the two can only be made looking at
relapse after cessation of steroid treatment. In these cases, we
would recommend using steroids alone for 3–6 months and then
taper treatment under close monitoring [6].
We would like to add another potential mechanism of action
of inﬂiximab, which is the induction of apoptosis in activated T
cells, thus contributing to the treatment effects observed [7].
Infectious complications are frequent with such treatment
and close monitoring of these patients seems essential. Indeed,
it appears that cirrhotic AIH patients under immunosuppressive
treatment are at particular risk of developing infections. The
patients presented in our series all had prior treatment with
other immunosuppressive agents, posing an additional risk.
Yet, as it is known from the use of biologicals in rheumatic dis-
eases, the risk is only slightly elevated for TNFa blockers [8]; in
fact it seems to be lower than with the use of steroids >15 mg/
diem [9]. We believe that the side effect proﬁle of inﬂiximab
on the long term is favorable as compared to calcineurin inhib-
itors, which have been proposed by Saitis and colleagues.
Mycophenolate mofetil serves well as a drug for patients with
intolerance to azathioprine, but in our hands rarely induces
remission in those with inadequate response to azathioprine
[10]. As discussed [11], we do not see it as ﬁrst-line treatment
in patients with AIH.
We therefore agree that – as also stated in our manuscript –
inﬂiximab can be considered a rescue treatment for patients with
difﬁcult-to-treat AIH. We feel that use of inﬂiximab offers
another treatment option for patients not responding to standard
ﬁrst- or second-line treatment. Close monitoring, not only for
infectious complications but also for parameters of disease activ-
ity, is indispensable in the off-label rescue treatment of AIH with
inﬂiximab.
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